Literature DB >> 24916775

[Serous ovarian tumors].

J Diebold1.   

Abstract

Because of different patterns of molecular changes, a dualistic model of serous tumors is now assumed with serous borderline tumors (SBT) and low-grade serous carcinomas (LGSC) on one side and high-grade serous carcinomas (HGSC) on the other. The clinical course and the type of treatment of SBT and LGSC depend crucially on whether they are associated with extraovarian manifestations. So-called invasive implants of SBT correspond morphologically to LGSC. The MD Anderson grading system has become established for the distinction between LGSC and HGSC, HGSC shows a wide range of growth patterns, including a transitional epithelial-like type. Carcinosarcomas can be interpreted as HGSC variants. Considering the new theory that all serous neoplasms of the ovary, peritoneum and fallopian tubes are derived from the tubal fimbria, the term "ovarian carcinoma" seems no longer appropriate.

Entities:  

Mesh:

Year:  2014        PMID: 24916775     DOI: 10.1007/s00292-014-1906-2

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  21 in total

1.  Grading of ovarian carcinomas.

Authors:  D Mayr; J Diebold
Journal:  Int J Gynecol Pathol       Date:  2000-10       Impact factor: 2.762

2.  Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up.

Authors:  Y Shimizu; S Kamoi; S Amada; F Akiyama; S G Silverberg
Journal:  Cancer       Date:  1998-03-01       Impact factor: 6.860

Review 3.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Hum Pathol       Date:  2011-07       Impact factor: 3.466

4.  Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry.

Authors:  Rola H Ali; Steve E Kalloger; Jennifer L Santos; Kenneth D Swenerton; C Blake Gilks
Journal:  Int J Gynecol Pathol       Date:  2013-11       Impact factor: 2.762

5.  Calculator for ovarian carcinoma subtype prediction.

Authors:  Steve E Kalloger; Martin Köbel; Samuel Leung; Erika Mehl; Dongxia Gao; Krista M Marcon; Christine Chow; Blaise A Clarke; David G Huntsman; C Blake Gilks
Journal:  Mod Pathol       Date:  2010-12-03       Impact factor: 7.842

6.  "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer.

Authors:  Jeffrey D Seidman; Po Zhao; Anna Yemelyanova
Journal:  Gynecol Oncol       Date:  2010-12-14       Impact factor: 5.482

7.  Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma.

Authors:  Russell Vang; Kala Visvanathan; Amy Gross; Emily Maambo; Mamta Gupta; Elisabetta Kuhn; Rose Fanghong Li; Brigitte M Ronnett; Jeffrey D Seidman; Anna Yemelyanova; Ie-Ming Shih; Patricia A Shaw; Robert A Soslow; Robert J Kurman
Journal:  Int J Gynecol Pathol       Date:  2012-05       Impact factor: 2.762

8.  K-RAS mutations in ovarian and extraovarian lesions of serous tumors of borderline malignancy.

Authors:  Joachim Diebold; Florian Seemüller; Udo Löhrs
Journal:  Lab Invest       Date:  2003-02       Impact factor: 5.662

9.  Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.

Authors:  Yevgeniy Karamurzin; Mario M Leitao; Robert A Soslow
Journal:  Am J Surg Pathol       Date:  2013-03       Impact factor: 6.394

10.  Ovarian carcinosarcoma associated with bilateral tubal intraepithelial carcinoma: a case report.

Authors:  Hermann Brustmann
Journal:  Int J Gynecol Pathol       Date:  2013-07       Impact factor: 2.762

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.